PharMerica (PMC) Tops Q3 EPS by 3c; Updates FY12 Outlook
Tweet
Share
E-mailGet Alerts PMC Hot Sheet
Join SI Premium – FREE
PharMerica (NYSE: PMC) reported Q3 EPS of $0.33, $0.03 better than the analyst estimate of $0.30. Revenue for the quarter came in at $442 million versus the consensus estimate of $446.36 million.
PharMerica sees FY2012 EPS of $1.15-1.24, versus prior guidance of $1.05-1.28 and the consensus of $1.22. PharMerica sees FY2012 revenue of $1.825-1.835 billion, versus prior guidance of $1.815-1.845 billion and the consensus of $1.84 billion.
For earnings history and earnings-related data on PharMerica (PMC) click here.
PharMerica sees FY2012 EPS of $1.15-1.24, versus prior guidance of $1.05-1.28 and the consensus of $1.22. PharMerica sees FY2012 revenue of $1.825-1.835 billion, versus prior guidance of $1.815-1.845 billion and the consensus of $1.84 billion.
For earnings history and earnings-related data on PharMerica (PMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Calamp Corp. (CAMP) Misses Q2 EPS by 33c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
